Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 6, 2014, Pages 1299-1307

  Lee, Sun Jae ^a   Hwang, Ji Won ^a   Yim, Hyungshin ^b   Yim, Hyung Joon ^a   Woo, Sang Uk ^b   Suh, Sang Jun ^a   Hyun, Jong Jin ^a   Jung, Sung Woo ^a   Koo, Ja Seol ^a   Kim, Ji Hoon ^a   Seo, Yeon Seok ^a   Yeon, Jong Eun ^a   Lee, Sang Woo ^a   Byun, Kwan Soo ^a   Um, Soon Ho ^a  

^a Korea University College of Medicine   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Combination drug therapy; Cyclooxygenase 2 inhibitor; Hepatocellular carcinoma; Simvastatin

Indexed keywords

ALPHA TUBULIN; CASPASE 9; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROCASPASE 3; PROCASPASE 8; PROTEIN BAX; PROTEIN BCL 2; SIMVASTATIN; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; ONCOPROTEIN; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; LIVER CELL CARCINOMA; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN LOCALIZATION; WESTERN BLOTTING; CELL TRANSFORMATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; NF-KAPPA B; NITROBENZENES; ONCOGENE PROTEIN V-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIMVASTATIN; SULFONAMIDES;

EID: 84900563613     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12503     Document Type: Article

References (39)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999; 340: 745-750.
3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
5. Llovet JM, Real MI, Montaña X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
6. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-390.
7. Shiota G, Okubo M, Noumi T etal. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 407-412.
8. Hida T, Yatabe Y, Achiwa H etal. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58: 3761-3764.
9. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58: 362-366.
10. Sumitani K, Kamijo R, Toyoshima T etal. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J. Oral Pathol. Med. 2001; 30: 41-47.
11. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin. Cancer Res. 2005; 11: 8213-8221.
12. Gao J, Jia WD, Li JS etal. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice. J. Int. Med. Res. 2010; 38: 1413-1427.
13. Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int. J. Mol. Med. 2010; 26: 735-741.
14. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr. Cancer Drug Targets 2009; 9: 626-638.
15. Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr. Cancer Drug Targets 2006; 6: 15-37.
16. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 2008; 415: 333-344.
17. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006; 6: 184-192.
18. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
19. Erdal E, Ozturk N, Cagatay T, Eksioglu-Demiralp E, Ozturk M. Lithium-mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells. Int. J. Cancer 2005; 115: 903-910.
20. Bettermann K, Vucur M, Haybaeck J etal. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010; 17: 481-496.
21. Kern MA, Schubert D, Sahi D etal. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36: 885-894.
22. Cheng AS, Chan HL, Leung WK, Wong N, Johnson PJ, Sung JJ. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int. J. Oncol. 2003; 23: 113-119.
23. Spampanato C, De Maria S, Sarnataro M etal. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int. J. Oncol. 2012; 40: 935-941.
24. Hasegawa K, Torii Y, Ishii R, Oe S, Kato R, Udagawa Y. Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch. Gynecol. Obstet. 2011; 284: 1515-1521.
25. Soh JW, Kazi JU, Li H, Thompson WJ, Weinstein IB. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol. Carcinog. 2008; 47: 519-525.
26. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004; 18: 2195-2224.
27. Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors 2007; 29: 19-35.
28. Aberg M, Wickström M, Siegbahn A. Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb. Res. 2008; 122: 191-202.
29. Huang CH, Guh JH, Chen GS, Lu PH, Chern JW. Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-kappaB and crosstalk between the extrinsic and intrinsic apoptotic pathways. Naunyn Schmiedebergs Arch. Pharmacol. 2010; 382: 159-169.
30. Vaish V, Tanwar L, Sanyal SN. The role of NF-kappaB and PPARgamma in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors. Tumour Biol. 2010; 31: 427-436.
31. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004; 206: 193-199.
32. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-85.
33. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc. Natl Acad. Sci. U.S.A. 1998; 95: 7439-7444.
34. Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell 2009; 138: 838-854.
35. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006; 43: S31-44.
36. Campbell MS, Makar GA. Safety of short-term administration of celecoxib in decompensated cirrhosis. Hepatology 2005; 42: 237; Author reply 8.
37. Clària J, Kent JD, López-Parra M etal. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41: 579-587.
38. Abraldes JG, Albillos A, Bañares R etal. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-1658.
39. Abraldes JG, Rodríguez-Vilarrupla A, Graupera M etal. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J. Hepatol. 2007; 46: 1040-1046.